Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Open Orphan Plc LSE:ORPH London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.30 -1.22% 24.20 23.50 24.50 25.00 23.80 24.50 2,081,930 16:35:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3.3 -5.6 -3.4 - 162

Open Orphan Share Discussion Threads

Showing 9826 to 9849 of 12350 messages
Chat Pages: Latest  398  397  396  395  394  393  392  391  390  389  388  387  Older
DateSubjectAuthorDiscuss
23/11/2020
12:12
CHIMagents Covid CHIM in consultation with European Medicines Agency (EMA) ‘EMA is providing guidance to assist developers of potential COVID-19 medicines, to prepare for eventual applications for marketing authorisation.’ CHAG-COVID19-CA ChimAgents Challenge agent for human infection models Non-clinical phase https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19 Good to see ORPH liaising with the EMA, in order to progress the Covid CHIM challenge agent in Europe. Subsequent EMA authorisation will be a step change for ORPH and enable it to potentially utilise the Covid CHIM at the third facility (presumed 45 bedroom CHIM unit at SGS in Belgium). IMHO
trader_3
23/11/2020
11:45
Qantas refusing to allow people to fly without a proof of vaccine so I heard
lazarus2010
23/11/2020
11:28
Another big growth area for ORPH is testing antibiotics. With resistance to antibiotics now a major world health problem Pharma companies have pledged to invest big time in developing new antibiotics. Government funding towards this will grow too! https://sports.yahoo.com/amphtml/drugs-companies-pledge-to-tackle-looming-health-threats-151500264.html
bobsworth
23/11/2020
11:12
Warranty. my opinion as a pharma layman (so worth fa really) is that they currently know very little about the vaccines, so even basic questions can't be answered with a high degree of accuracy. let alone the questions you pose. I'm surprised at the oxford prof on r4 today, the leader of the astra zeneca vaccine iirc. Scientists are supposed to be understated (since they know many things are unknown) and not outrightly bullish and oh so positive on what is extremely preliminary data. I suppose he's also a director of several small pharmas, and possibly even big ones, and so may have a vested interest. I don't like the mixture of acandemia and commercial (although orph has prof buckly and prof oxford in the bacground) to the extend of academcs being major shareholders. In the past, i'd say there'd be no conflict there, with the rigours of science winning out, but nowadays, i'd say there's a real conflict in pharma science (similar to climate science) where science is trumped by other considerations. Orph doesn't need more challenge study opportunities. It's full and overflowing with them already. If we get another clinic (= another 20mpa profit imv), then that will be full very quickly. The demand is insatiable, and will be for several years imv.
pierre oreilly
23/11/2020
11:08
I think it would have been wiser to start with youngsters and work upwards rather than the opposite way round. It would have been enough for the old to vaccinate their carers and family first, to build local immunity. As it is they risk confirming what we already know - that covid is much worse for the elderly - and discovering that that may also be true for a vaccine.
supernumerary
23/11/2020
10:58
Do we know if the various vaccines can be mixed, ie a Pfizer one this year then an AZ one next and also could there be any clash with flu jabs on the old whose immune systems may not be brilliant? Still so many questions on these vaccines so hopefully more opportunities for Orph?
warranty
23/11/2020
10:25
yes, Irish citizens have privileges in Uk under the Common Travel Area, they are treated almost as Uk citizens and can even vote ? This is a historical legacy
thomas11
23/11/2020
10:22
"Watch out for her 'standing down to pursue family interests' if/when she's lent on" LOL. Exactly. I will be in the same queue as you Pierre.
m5
23/11/2020
10:21
o/t, will southern irish people have a right of residence in the uk after dec 31 and vv?
pierre oreilly
23/11/2020
10:18
M, agree with all that. Zero effect on orph, all beeb reports really nonsense bullish uselesness designed to jockey everyone along. Some sense the other day with the lady boss of the mhra, saying from her perspective, when a company applies for a covid vaccine authorisation, her committee will judge the application in exactly the same way as any other vaccine. Watch out for her 'standing down to pursue family interests' if/when she's lent on. I think that's the only way we'll get an authorised vaccine before 2021 (and i'll not be turning up for a covid jab until 3 or 4 months after the first jabs have been given).
pierre oreilly
23/11/2020
09:34
I think I will be passing on them all for now. Not in a particularly vulnerable category and the testing period before main stream roll out just seems ridiculous to me. I can't help thinking this is all Political gesturing and playing for time. Can't see why it would affect us Malcolm as we know testing will continue for a long long time. As CF said Covid is not going away. IMHO. A comment from elsewhere........ Very interesting to see half a dose then a full dose thereafter working much better than a two full doses for the Oxford vaccine. Huge scope to trial various vaccines at different dose rates to find most effective model for wider roll out in future. Lots of work for Hvivo!!!
m5
23/11/2020
09:16
offered 24.72p for large amounts online even after Oxford Astra Zeneca's good news on their vaccination. I personally would much rather have the Oxford vaccine than the Pfizer offering as I am thinking anything having to be kept at a constant -70c would be in danger of contamination due to a drop in temperature and perhaps start growing bat wings ha ha
malcolmmm
23/11/2020
08:54
StockBox Podcast - ORPH hxxps://www.pscp.tv/w/1YqJDevvLOBxV
trader_3
22/11/2020
11:44
https://www-irishexaminer-com.cdn.ampproject.org/v/s/www.irishexaminer.com/business/economy/arid-40085546.html?amp_js_v=a6&_gsa=1&type=amp&usqp=mq331AQFKAGwASA%3D#aoh=16060444763889&csi=1&referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Fwww.irishexaminer.com%2Fbusiness%2Feconomy%2Farid-40085546.html
timmyb1
22/11/2020
11:03
Guardian Paper: Why the race to find Covid-19 vaccines is far from over https://www.theguardian.com/world/2020/nov/22/why-the-race-to-find-covid-19-vaccines-is-far-from-over Small mention of challenge studies.
trader_3
22/11/2020
09:20
From the DM The healthcare industry, and in particular pharmaceutical giants, has struggled for the past two decades to produce new blockbuster drugs. However, the need, value and importance of having quick and successful treatments has never been clearer given the current circumstances. There is the potential for major breakthroughs in drug discovery as IT and data analytics improve productivity in therapy, and provide more targeted treatment. China is a growing market for drug development. It has a large amount of cancer patients, and one in two of those are in drug trials, compared to one in 20 in the US. There is a huge amount of data being collected through apps and monitoring tools. Wearable devices such as Fitbit often sync with other health apps to present your data. Funds to take advantage of this growing theme are ASI Global Smaller Companies is overweight healthcare. Manager Harry Nimmo focuses on change and looks for companies which offer the best combination of growth, quality and trade at attractive values.
judijudi
22/11/2020
07:50
Imo one good thing is that now we are are out of Europe we don't have to adhere to all their ethical laws etc which can take years to get permissions for challenge studies etc.Also the government is going to massively slash tariffs for trade with third world countries which is far better than aid and not possible in the self serving EU.
malcolmmm
21/11/2020
15:56
hVIVO RSV PC786 Paper Published ‘PC786 is a new medicine being developed for treatment of respiratory syncytial virus. The main purpose of this study is to evaluate the antiviral activity of PC786 in healthy adults infected with RSV virus in a viral challenge study.’ Nice to see positive results coming from the PC786 RSV hVIVO study being released for Pulmocide Ltd : hxxps://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa716/5995608 Whilst this study pre dates Open Orphan, it further demonstrates the benefits and effectiveness of conducting challenge services through hVIVO.
trader_3
21/11/2020
15:27
Getting the impression this is still at the foothills, sounds like a lot of growth to come here. WRT expansion via further facility, it sounded to me like they're already performing work with another company and news flow to follow soon.
owenski
21/11/2020
15:10
Challenge Study volunteer 6 minute interesting view on Ted Talks Daily Podcast:- htTps://www.ted.com/talks/sophie_rose_how_covid_19_human_challenge_trials_work_and_why_i_volunteered/up-next?rss=172BB350-0207#t-10453
40plus
21/11/2020
14:43
Just listened the the Proactive presentation. Probably his "best" yet. CF was calm, more focused, but did not hesitate to spell out the great opportunities OO has over the coming years. I thought that I was fully invested, but will be looking to buy more. The impressio ngiven was that some of the bigger newsflow we are expecting may come before Christmas. hTTps://youtu.be/RL4si_KAuDI
wassapper
21/11/2020
13:02
I have my sons junior isa with Interactive Investor, the charges may be a bit higher than others but if the account is in your name which it will be for your child you can have as many other accounts as you want for a flat monthly fee. So for example I have a junior isa, my isa and a trading account all in my name for a flat monthly fee.
ironman22
21/11/2020
12:27
I suspect the move to London has as much to do with tax planning as anything else. Presumably he'd have resident non-dom status here, which although not as valuable as it once was, I imagine still has benefits. Hugely complex though and requires very careful planning. He may not have been so concerned when he thought he was going to make a few millions and move on, but if he thinks it's going to be tens of millions, it's worth taking every possible precaution.
supernumerary
21/11/2020
12:24
Thanks gents 👌
bobdobalina
Chat Pages: Latest  398  397  396  395  394  393  392  391  390  389  388  387  Older
ADVFN Advertorial
Your Recent History
LSE
ORPH
Open Orpha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210127 20:22:18